Skip to main content

Table 1 Number and percentage of cases according to components of therapy in patients with KD at the NUNH Hospital in patients in the 19th Nationwide survey (2005–6) and the first cohort (low-dose IVIG)

From: Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study

  19thNationwide survey (2005–2006) First cohort (2004–2008) p-value
Total 20,475 100.0 126 100.0  
Dosage of IVIG Cases % Cases %  
2 g/kg 11,612 56.7 3 2.1 0.001
1 g/kg/day × 2 d 4,800 23.4 3 2.1 0.001
400 mg/kg/day × 5 d 231 1.1 95 75.4 0.001
Various dosages of IVIG 879 4.3 0 0 0.01
Aspirin alone (no IVIG) 2,866 14.0 25 19.8 0.07
Dalteparin 0 0 126 100.0  
Age (months) -* 22 (0–167)  
Male sex 11,892 (58.1%) 68 (54.0%) 0.37
  1. KD: Kawasaki disease; NUNH Hospital: Nihon University Nerima-Hikarigaoka Hospital; IVIG: intravenous immunoglobulin.
  2. Dalteparin was administered until the patient was afebrile, clinically improving, and/or showed a C-reactive protein (CRP) < 1.0 mg/dL.
  3. Data are median (range), n (%).
  4. *The highest prevalence was observed among those aged 6–8 months [17].